{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intron+A%2C+Interferon+alpha+-2b&page=2",
    "query": {
      "intervention": "Intron A, Interferon alpha -2b",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intron+A%2C+Interferon+alpha+-2b&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T04:33:31.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00886457",
      "title": "5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Decitabine and Pegylated Interferon-Alfa 2B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nevada Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2009-04",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2011-07-20",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00886457"
    },
    {
      "nct_id": "NCT00217542",
      "title": "Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Recurrent Renal Cell Cancer",
        "Stage III Melanoma",
        "Stage IV Melanoma",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine/azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217542"
    },
    {
      "nct_id": "NCT00101114",
      "title": "Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Recurrent Renal Cell Cancer",
        "Stage III Renal Cell Cancer",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 55,
      "start_date": "2004-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101114"
    },
    {
      "nct_id": "NCT00002556",
      "title": "Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "1994-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002556"
    },
    {
      "nct_id": "NCT00467077",
      "title": "Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "PEG-interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "California Cancer Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 21,
      "start_date": "2004-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467077"
    },
    {
      "nct_id": "NCT04081389",
      "title": "Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage 0 Breast Cancer AJCC v8",
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Anatomic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Early-Stage Breast Carcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Progesterone Receptor Negative",
        "Prognostic Stage 0 Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2019-12-06",
      "completion_date": "2023-02-27",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04081389"
    },
    {
      "nct_id": "NCT00746746",
      "title": "A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "HyperAcute vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated Interferon-Alpha 2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ochsner Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-06",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-01-13",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00746746"
    },
    {
      "nct_id": "NCT01405027",
      "title": "Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C",
        "Genotype 1"
      ],
      "interventions": [
        {
          "name": "Educational Intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "Patient education and management skills training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Chronic Liver Disease Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2011-12",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-01-06",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 43,
      "location_summary": "Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Calabasas",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01405027"
    },
    {
      "nct_id": "NCT00062010",
      "title": "Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "interferon alpha",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13-cis-retinoic acid",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2004-05-26",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 73,
      "location_summary": "Decatur, Georgia • Aurora, Illinois • Hinsdale, Illinois + 45 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Aurora",
          "state": "Illinois"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062010"
    },
    {
      "nct_id": "NCT04418219",
      "title": "Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Recurrent Breast Carcinoma",
        "Refractory Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Interferon Alpha 2b-like Protein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality of Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2020-12-21",
      "completion_date": "2024-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-29T04:33:31.784Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418219"
    }
  ]
}